Tag: chronic wound care

FDA Clears Drug-Device Combination Matrix for Chronic Wound Care

The US Food and Drug Administration (FDA) has cleared the Omeza Collagen Matrix, a drug-device combination matrix for chronic wound care … The approval was granted through the FDA 510(k) premarket notification process. It is the first combination drug/device designed for chronic wound care … The wound care matrix is composed of hydrolyzed fish collagen infused with cod liver oil and other plant-derived oil and wax. After it is applied to a wound, the matrix is incorporated into the wound over time … read more

Thermal Imaging Offers Early Alert for Chronic Wound Care

New research shows thermal imaging techniques can predict whether a wound needs extra management, offering an early alert system to improve chronic wound care … It is estimated that 1-2% of the population will experience a chronic wound during their lifetime in developed countries. In the U.S., chronic wounds affect about 6.5 million patients with more than $25 billion each year spent by the healthcare system on treating related complications … read more

Thermal imaging offers early alert for chronic wound care

New research shows thermal imaging techniques can predict whether a wound needs extra management, offering an early alert system to improve chronic wound care … It is estimated that 1-2% of the population will experience a chronic wound during their lifetime in developed countries – in the US, chronic wounds affect about 6.5 million patients with more than US$25 billion each year spent by the healthcare system on treating related complications … The Australian study shows textural analysis of thermal images of venous leg ulcers (VLUs) can detect whether a wound needs extra management as early as week two for clients receiving treatment at home … read more

TissueTech, Inc. Awarded Patent for Compositions of

Morselized Umbilical Cord and Amniotic Membrane

 

MIAMI–(BUSINESS WIRE)–TissueTech Inc., the pioneer in the development and clinical application of regenerative amniotic tissue-based products, announced that it has been awarded patent 9,808,491 by the U.S. Patent Trademark Office. The patent applies to the use of a gel composition comprising morselized placental amniotic membrane and/or morselized umbilical cord. as a method for treating an ocular wound or repairing damaged ocular tissue.

 

“TissueTech has been the leader in the development and clinical application of amniotic membrane transplantation for the treatment of a variety of patient conditions in ophthalmology, chronic wound care, orthopedics and sports medicine,” said Amy Tseng, Chief Executive Officer of TissueTech. “We are excited that this patent represents our continued innovation and is another step forward in excelling our technological advances in the industry.”

read more